Analyst Information


Yasmeen Rahimi, Ph.D.

Sr. Research Analyst

Yasmeen Rahimi, Ph.D.

Yasmeen Rahimi is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in July 2020, Rahimi was a senior research analyst and co-head of biotechnology equity research team at ROTH Capital Partners. Before that, she worked as an equity research associate at H.C. Wainwright & Co. and Guggenheim Securities. Prior to making the transition to Wall Street, Rahimi was a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of rare disease programs; she has an extensive expertise in liver metabolism. Rahimi trained as a postdoctoral fellow at Yale University in the laboratory of Gerald Shulman after completing her Ph.D. from Indiana University School of Medicine. In addition, she has a M.S. in Bioanalytical Chemistry from Purdue University and a joint B.A. in German and Chemistry from Butler University.

Universe Coverage:
Healthcare:   Biotechnology
ETNB89bio, Inc.
ALBOAlbireo Pharma, Inc.
ALGSAligos Therapeutics, Inc.
ALTAltimmune, Inc.
AMRNAmarin Corp. Plc
ARCTArcturus Therapeutics Holdings, Inc.
AXLAAxcella Therapeutics
CBAYCymaBay Therapeutics Inc.
CYTKCytokinetics, Incorporated
DSGNDesign Therapeutics, Inc.
ENTAEnanta Pharmaceuticals, Inc.
GOSSGossamer Bio
IMUXImmunic, Inc.
ICPTIntercept Pharmaceuticals, Inc.
LMNLLiminal BioSciences, Inc.
LUMOLumos Pharma, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals, Inc.
NGMNGM Biopharmaceuticals, Inc.
PRAXPraxis Precision Medicines, Inc.
PTGXProtagonist Therapeutics, Inc.
RPHMReneo Pharmaceuticals, Inc.
SAGESage Therapeutics, Inc.
SVRASavara, Inc.
TNYATenaya Therapeutics, Inc.
VXRTVaxart, Inc.
VTYXVentyx Biosciences, Inc.